Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co ROE % Adjusted to Book Value Chart
Qinghai Spring Medicinal Resources Technology Co Annual Data
SHSE:600381 vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qinghai Spring Medicinal Resources Technology Co ROE % Adjusted to Book Value vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -3.61% mean?
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) has a ROE % Adjusted to Book Value of -3.61% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors.
Is Qinghai Spring Medicinal Resources Technology Co's ROE % Adjusted to Book Value too high?
Qinghai Spring Medicinal Resources Technology Co's current ROE % Adjusted to Book Value is -3.61%. Overall, Qinghai Spring Medicinal Resources Technology Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qinghai Spring Medicinal Resources Technology Co's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Qinghai Spring Medicinal Resources Technology Co's ROE % Adjusted to Book Value of -3.61% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. Qinghai Spring Medicinal Resources Technology Co's current ROE % Adjusted to Book Value is -3.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qinghai Spring Medicinal Resources Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥4.20 — trading 28.2% below its estimated fair value. The current ROE % Adjusted to Book Value is -3.61%. Qinghai Spring Medicinal Resources Technology Co's overall GF Score™ is 64/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Qinghai Spring Medicinal Resources Technology Co (SHSE:600381), the current ROE % Adjusted to Book Value is -3.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Overvalued in 2026?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co stock appears to be undervalued.
The current stock price of ¥4.20 is trading 28.2% below its estimated GF Value™ of ¥5.85.
GuruFocus considers Qinghai Spring Medicinal Resources Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:600381:
ROE % Adjusted to Book Value: -3.61%
GF Value™: ¥5.85 vs. price of ¥4.20 (28.2% below fair value)
No single metric tells the full story. See the SHSE:600381 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qinghai Spring Medicinal Resources Technology Co Business Description
Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.
64GF Score
Get the complete analysis for SHSE:600381
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600381 has been successfully added to your 
